Literature DB >> 12113874

Urinary tract infections in patients with diabetes.

Ann Stapleton1.   

Abstract

Results of various epidemiologic studies suggest that bacteriuria and urinary tract infection (UTI) occur more commonly in women with diabetes than in women without this disease. Similar findings have been demonstrated for asymptomatic bacteriuria (ASB), with ASB being a risk factor for pyelonephritis and subsequent decline in renal function. Although ASB is not associated with serious health outcomes in healthy patients, further research needs to be undertaken regarding the impact of ASB in patients with diabetes. Patients with diabetes often have increased complications of UTI, including such rare complications as emphysematous cystitis and pyelonephritis, fungal infections (particularly Candida species), and increased severity and unusual manifestations (e.g., gram-negative pathogens other than Escherichia coli). Anatomic and functional abnormalities of the urinary tract are also associated with diabetes. Such abnormalities result in greater instrumentation of the urinary tract, thereby increasing the risk of secondary UTI. In addition, these abnormalities complicate UTI and require specialized treatment strategies. There is a greater likelihood of UTI affected by antimicrobial resistance or atypical uropathogens, and the risk of upper tract involvement is increased. Pre- and posttherapy urine cultures are therefore indicated. The initial choice of empiric antimicrobial therapy should be based on Gram stain and urine culture. Choice of antibiotic therapy should integrate local sensitivity patterns of the infecting organism. Fluoroquinolones are a reasonable empiric choice for many patients with diabetes. For seriously ill patients, including patients infected with Pseudomonas spp., such agents as imipenem, ticarcillin-clavulanate, and piperacillin-tazobactam may also be considered. Treatment of ASB in patients with diabetes is often recommended to prevent the risk of symptomatic UTI. However, the management of ASB in patients with diabetes is complex, with no single preferred approach.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113874     DOI: 10.1016/s0002-9343(02)01062-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  46 in total

1.  Emphysematous cystitis: radiological diagnosis of complicated urinary tract infection.

Authors:  Seshikanth Middela; Euan Green; Richard Montague
Journal:  BMJ Case Rep       Date:  2009-12-09

2.  Emphysematous pyelonephritis: Our experience in managing these cases.

Authors:  Fatih Uruc; Ozgur Haki Yuksel; Aytac Sahin; Ahmet Urkmez; Caglar Yildirim; Ayhan Verit
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

3.  Diabetes mellitus and the risk of urolithiasis: a meta-analysis of observational studies.

Authors:  Lu Hao Liu; Ran Kang; Jun He; Shan Kun Zhao; Fu Tian Li; Zhi Gang Zhao
Journal:  Urolithiasis       Date:  2015-04-17       Impact factor: 3.436

4.  Imaging of acute pyelonephritis in the adult.

Authors:  H Stunell; O Buckley; J Feeney; T Geoghegan; R F J Browne; W C Torreggiani
Journal:  Eur Radiol       Date:  2006-08-26       Impact factor: 5.315

Review 5.  Candida infections of the genitourinary tract.

Authors:  Jacqueline M Achkar; Bettina C Fries
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  Palmitate induced IL-6 and MCP-1 expression in human bladder smooth muscle cells provides a link between diabetes and urinary tract infections.

Authors:  Andreas Oberbach; Nadine Schlichting; Matthias Blüher; Peter Kovacs; Holger Till; Jens-Uwe Stolzenburg; Jochen Neuhaus
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

7.  Prevalence of lower urinary tract infection in South Indian type 2 diabetic subjects.

Authors:  J Janifer; S Geethalakshmi; K Satyavani; V Viswanathan
Journal:  Indian J Nephrol       Date:  2009-07

8.  Glycemic Control and Urinary Tract Infections in Women with Type 1 Diabetes: Results from the DCCT/EDIC.

Authors:  Sara M Lenherr; J Quentin Clemens; Barbara H Braffett; Patricia A Cleary; Rodney L Dunn; James M Hotaling; Alan M Jacobson; Catherine Kim; William Herman; Jeanette S Brown; Hunter Wessells; Aruna V Sarma
Journal:  J Urol       Date:  2016-04-27       Impact factor: 7.450

Review 9.  Current management of emphysematous pyelonephritis.

Authors:  Alan R Pontin; Richard D Barnes
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

10.  Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents.

Authors:  Soulmaz Fazeli Farsani; Patrick C Souverein; Marja M J van der Vorst; Catherijne A J Knibbe; Anthonius de Boer; Aukje K Mantel-Teeuwisse
Journal:  Antimicrob Agents Chemother       Date:  2014-06-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.